Home   Business   Article

Subscribe Now

PhoreMost and ThinkCyte to collaborate on AI-powered drug discovery




PhoreMost and ThinkCyte are collaborating to advance AI-based drug discovery.

The strategic research partnership is aimed at advancing modern phenotypic drug screening using AI.

PhoreMost CEO Chris Torrance. Picture: Keith Heppell
PhoreMost CEO Chris Torrance. Picture: Keith Heppell

Unity Campus-based PhoreMost is dedicated to ‘Drugging the Undruggable’ disease targets, while Japan-based ThinkCyte KK is a biotech company pioneering novel cell analysis and sorting instruments.

The partnership leverages both companies’ distinctive technologies in high-throughput drug discovery. PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterisation and sorting platform, Ghost Cytometry, will work together with the aim of developing differentiated therapies for a range of diseases with unmet clinical need.

Dr Benedict Cross, CTO of PhoreMost, said: “PhoreMost has embraced the revolution in computational methods to transform the way we approach modern drug discovery.

“By combining ThinkCyte’s AI-based platform to detect novel, disease-related phenotypes with our SITESEEKER phenotypic screening platform, we hope to more efficiently uncover a broad range of novel targets and translate them into high-quality first-in-class therapeutic assets”

Waichiro Katsuda, CEO at ThinkCyte, added: “We are very excited about the research partnership with PhoreMost, a leader in applying innovative approaches and technologies to open up new druggable spaces.

“We have been privileged to work with drug discovery industry partners who share our vision of using AI to rethink traditional approaches in R&D and look forward to working together with PhoreMost to advance our technologies towards the shared goal of making meaningful impact for people suffering from serious diseases.”



Comments | 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More